Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy

European Journal of Pharmaceutical Sciences

Volumn 45, Issue 4, 2012, Pages 388-398

  Gabizon, Alberto ^a   Shmeeda, Hilary ^a   Grenader, Tal ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cancer; Doxorubicin; Liposome; Pegylation; Pharmacokinetics

Indexed keywords

AMIFOSTINE; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; TRABECTEDIN; TRASTUZUMAB; VALSPODAR; VINCRISTINE;

ALOPECIA; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD VESSEL PERMEABILITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER THERAPY; CARDIOTOXICITY; CIRCULATION TIME; CONFERENCE PAPER; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; KAPOSI SARCOMA; LEUKOPENIA; MALIGNANT MENINGIOMA; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SENSORY NEUROPATHY; SKIN TOXICITY; SOFT TISSUE SARCOMA; STOMATITIS; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; HUMANS; NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 84856279574     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.09.006     Document Type: Conference Paper

References (89)

1. R.M. Abra, R.B. Bankert, F. Chen, N.K. Egilmez, K. Huang, R. Saville, J.L. Slater, M. Sugano, and S.J. Yokota The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients J. Liposome Res. 12 2002 1 3 (Pubitemid 34846950)
2. S.E. Al-Batran, M. Guntner, C. Pauligk, M. Scholz, R. Chen, B. Beiss, S. Stopatschinskaja, W. Lerbs, N. Harbeck, and E. Jager Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials Br. J. Cancer 103 2010 1518 1523
3. D.S. Alberts, F.M. Muggia, J. Carmichael, E.P. Winer, M. Jahanzeb, A.P. Venook, K.M. Skubitz, E. Rivera, J.A. Sparano, N.J. DiBella, S.J. Stewart, J.J. Kavanagh, and A.A. Gabizon Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials Semin. Oncol. 31 2004 53 90 (Pubitemid 40023242)
4. M. Amantea, M.S. Newman, T.M. Sullivan, A. Forrest, and P.K. Working Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs Hum. Exp. Toxicol. 18 1999 17 26 (Pubitemid 29054468)
5. M.A. Amantea, A. Forrest, D.W. Northfelt, and R. Mamelok Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma Clin. Pharmacol. Ther. 61 1997 301 311 (Pubitemid 27145431)
6. E. Andreopoulou, D. Gaiotti, E. Kim, A. Downey, D. Mirchandani, A. Hamilton, A. Jacobs, J. Curtin, and F. Muggia Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer Ann. Oncol. 18 2007 716 721 (Pubitemid 46523276)
7. M. Banciu, R.M. Schiffelers, and G. Storm Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil Pharm. Res. 25 2008 1948 1955
8. Y. Barenholz Relevancy of drug loading to liposomal formulation therapeutic efficacy J. Liposome Res. 13 2003 1 8 (Pubitemid 36378121)
9. V. Bozionelou, L. Vamvakas, P. Pappas, S. Agelaki, N. Androulakis, A. Kalykaki, M. Nikolaidou, N. Kentepozidis, S. Giassas, M. Marselos, V. Georgoulias, and D. Mavroudis A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours Br. J. Cancer 97 2007 43 49 (Pubitemid 47012090)
10. E. Briasoulis, V. Karavasilis, E. Tzamakou, D. Rammou, K. Soulti, C. Piperidou, and N. Pavlidis Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel Cancer Chemother. Pharmacol. 53 2004 452 457 (Pubitemid 38553669)
11. A. Cabanes, D. Tzemach, D. Goren, A.T. Horowitz, and A. Gabizon Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model Clin. Cancer Res. 4 1998 499 505 (Pubitemid 28122769)
12. G.J. Charrois, and T.M. Allen Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity J. Pharmacol. Exp. Ther. 306 2003 1058 1067 (Pubitemid 37025314)
13. S. Chia, M. Clemons, L.A. Martin, A. Rodgers, K. Gelmon, G.R. Pond, and L. Panasci Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial J. Clin. Oncol. 24 2006 2773 2778 (Pubitemid 46630575)
14. M. Cianfrocca, S. Lee, J. Von Roenn, A. Tulpule, B.J. Dezube, D.M. Aboulafia, R.F. Ambinder, J.Y. Lee, S.E. Krown, and J.A. Sparano Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy Cancer 116 2010 3969 3977
15. Colbern, G., Steinmetz, K., Musterer, R., Johnson, L., Hiller, A., Working, P., Bandak, S., Gabizon, A., 2000. Amifostine reduces severity and incidence of Doxil-induced palmar/plantar erythrodysesthesia in rats but does not reduce Doxil antitumor efficacy in mice. Proc. Am. Soc. Clin. Oncol. 19 (abstr. 815).
16. C. de la Fouchardiere, R. Largillier, Y. Goubely, A.C. Hardy-Bessard, B. Slama, J. Cretin, H. Orfeuvre, D. Paraiso, T. Bachelot, and E. Pujade-Lauraine Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE Ann. Oncol. 20 2009 1959 1963
17. E.C. Dees, B.H. O'Neil, C.M. Lindley, F. Collichio, L.A. Carey, J. Collins, W.J. Riordan, A. Ivanova, D. Esseltine, and R.Z. Orlowski A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors Cancer Chemother. Pharmacol. 63 2008 99 107
18. D.C. Drummond, C.O. Noble, Z. Guo, K. Hong, J.W. Park, and D.B. Kirpotin Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy Cancer Res. 66 2006 3271 3277
19. R. Duncan Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6 2006 688 701 (Pubitemid 44286001)
20. M.S. Ewer, F.J. Martin, C. Henderson, C.L. Shapiro, R.S. Benjamin, and A.A. Gabizon Cardiac safety of liposomal anthracyclines Semin. Oncol. 31 2004 161 181 (Pubitemid 40023246)
21. G. Ferrandina, G. Corrado, A. Licameli, D. Lorusso, G. Fuoco, S. Pisconti, and G. Scambia Pegylated liposomal doxorubicin in the management of ovarian cancer Ther. Clin. Risk Manag. 6 2010 463 483
22. P.M. Fracasso, K.A. Blum, M.K. Ma, B.R. Tan, L.P. Wright, S.A. Goodner, C.L. Fears, W. Hou, M.A. Arquette, J. Picus, A. Denes, J.E. Mortimer, L. Ratner, S.P. Ivy, and H.L. McLeod Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar Br. J. Cancer 93 2005 46 53 (Pubitemid 41076252)
23. Y. Fujisaka, A. Horiike, T. Shimizu, N. Yamamoto, Y. Yamada, and T. Tamura Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors Jpn. J. Clin. Oncol. 36 2006 768 774 (Pubitemid 47090731)
24. D. Fukumura, D.G. Duda, L.L. Munn, and R.K. Jain Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models Microcirculation 17 2010 206 225
25. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, and Y. Barenholz Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res. 54 1994 987 992 (Pubitemid 24085451)
26. A. Gabizon, D. Goren, A.T. Horowitz, D. Tzemach, A. Lossos, and T. Siegal Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals Adv. Drug Deliv. Rev. 24 1997 337 344 (Pubitemid 27112652)
27. A. Gabizon, R. Isacson, O. Rosengarten, D. Tzemach, H. Shmeeda, and R. Sapir An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin Cancer Chemother. Pharmacol. 61 2008 695 702
28. A. Gabizon, and F. Martin Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours Drugs 54 Suppl. 4 1997 15 21 (Pubitemid 27487791)
29. A. Gabizon, and D. Papahadjopoulos Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors Proc. Natl. Acad. Sci. USA 85 1988 6949 6953
30. A. Gabizon, and D. Papahadjopoulos The role of surface charge and hydrophilic groups on liposome clearance in vivo Biochim. Biophys. Acta 1103 1992 94 100
31. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42 2003 419 436 (Pubitemid 36649037)
32. A. Gabizon, D. Tzemach, L. Mak, M. Bronstein, and A.T. Horowitz Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models J. Drug Target. 10 2002 539 548 (Pubitemid 36124352)
33. A.A. Gabizon Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet Clin. Cancer Res. 7 2001 223 225 (Pubitemid 32183021)
34. A.A. Gabizon, O. Lyass, G.J. Berry, and M. Wildgust Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies Cancer Invest. 22 2004 663 669 (Pubitemid 40064725)
35. G. Giaccone, S.C. Linn, J. Welink, G. Catimel, H. Stieltjes, W.J. van der Vijgh, C. Eeltink, J.B. Vermorken, and H.M. Pinedo A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors Clin. Cancer Res. 3 1997 2005 2015 (Pubitemid 27505127)
36. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 19 2001 3312 3322 (Pubitemid 32642183)
37. A.N. Gordon, M. Tonda, S. Sun, and W. Rackoff Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol. Oncol. 95 2004 1 8 (Pubitemid 39286270)
38. T. Grenader, A. Goldberg, and A. Gabizon Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up? Anticancer Drugs 21 2010 868 871
39. T. Grenader, A. Goldberg, I. Hadas-Halperin, and A. Gabizon Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas Anticancer Drugs 20 2009 15 20
40. T. Grenader, F. Vernea, C. Reinus, and A. Gabizon Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin J. Clin. Oncol. 29 2011 e722 e724
41. A. Hamilton, L. Biganzoli, R. Coleman, L. Mauriac, P. Hennebert, A. Awada, M. Nooij, L. Beex, M. Piccart, I. Van Hoorebeeck, P. Bruning, and D. de Valeriola EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer Ann. Oncol. 13 2002 910 918 (Pubitemid 34752687)
42. Henry, D., Cooley, T., Volberding, P., Martin, F., Tonda, M., Kroll, M., 2002. Final results of a phase III randomized trial of Doxil vs DaunoXome in patients with AIDS-related Kaposi's sarcoma. Proc. Am. Soc. Clin. Oncol. 21 (abstr. 1640).
43. R.L. Hong, and Y.L. Tseng Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity Cancer 91 2001 1826 1833
44. R.L. Hong, and Y.L. Tseng A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma Cancer Chemother. Pharmacol. 51 2003 433 438
45. R.L. Hong, Y.L. Tseng, and F.H. Chang Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study Ann. Oncol. 11 2000 349 353
46. S.K. Huang, K.D. Lee, K. Hong, D.S. Friend, and D. Papahadjopoulos Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice Cancer Res. 52 1992 5135 5143
47. K.J. Hwang, K.F. Luk, and P.L. Beaumier Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study Proc. Natl. Acad. Sci. USA 77 1980 4030 4034 (Pubitemid 10022542)
48. I. Judson, J.A. Radford, M. Harris, J.Y. Blay, Q. van Hoesel, A. le Cesne, A.T. van Oosterom, M.J. Clemons, C. Kamby, C. Hermans, J. Whittaker, E. Donato di Paola, J. Verweij, and S. Nielsen Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 37 2001 870 877 (Pubitemid 32323965)
49. La-Beck, N.M., Zamboni, B.A., Gabizon, A., Schmeeda, H., Amantea, M., Gehrig, P.A., Zamboni, W.C., 2011. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother. Pharmacol. Epub: May 18.
50. D.D. Lasic, B. Ceh, M.C. Stuart, L. Guo, P.M. Frederik, and Y. Barenholz Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery Biochim. Biophys. Acta 1239 1995 145 156
51. D.D. Lasic, F.J. Martin, A. Gabizon, S.K. Huang, and D. Papahadjopoulos Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times Biochim. Biophys. Acta 1070 1991 187 192
52. M. Lotem, A. Hubert, O. Lyass, M.A. Goldenhersh, A. Ingber, T. Peretz, and A. Gabizon Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin Arch. Dermatol. 136 2000 1475 1480 (Pubitemid 32009267)
53. O. Lyass, A. Hubert, and A.A. Gabizon Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies Clin. Cancer Res. 7 2001 3040 3046 (Pubitemid 32963822)
54. Lyass, O., Lotem, M., Edelmann, D., Hubert, A., Gabizon, A., 2001b. Protective effect of amifostine on Doxil/Caelyx-induced palmar-plantar erythrodysesthesia (PPE) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 20 (abstr. 2148).
55. O. Lyass, B. Uziely, R. Ben-Yosef, D. Tzemach, N.I. Heshing, M. Lotem, G. Brufman, and A. Gabizon Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma Cancer 89 2000 1037 1047
56. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 41 2001 189 207
57. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284 (Pubitemid 30122932)
58. N.M. Marina, D. Cochrane, E. Harney, K. Zomorodi, S. Blaney, N. Winick, M. Bernstein, and M.P. Link Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study Clin. Cancer Res. 8 2002 413 418 (Pubitemid 34193958)
59. L. Martin-Carbonero, A. Barrios, P. Saballs, G. Sirera, J. Santos, R. Palacios, M.E. Valencia, M. Alegre, D. Podzamczer, and J. Gonzalez-Lahoz Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma AIDS 18 2004 1737 1740 (Pubitemid 39095795)
60. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
61. A.I. Minchinton, and I.F. Tannock Drug penetration in solid tumours Nat. Rev. Cancer 6 2006 583 592 (Pubitemid 44140857)
62. O.S. Nielsen, P. Reichardt, T.B. Christensen, D. Pink, S. Daugaard, C. Hermans, S. Marreaud, M. van Glabbeke, J. Blay, and I. Judson Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas Eur. J. Cancer 42 2006 2303 2309 (Pubitemid 44316905)
63. D.W. Northfelt, B.J. Dezube, J.A. Thommes, B.J. Miller, M.A. Fischl, A. Friedman-Kien, L.D. Kaplan, C. Du Mond, R.D. Mamelok, and D.H. Henry Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial J. Clin. Oncol. 16 1998 2445 2451 (Pubitemid 28309039)
64. D.W. Northfelt, F.J. Martin, P. Working, P.A. Volberding, J. Russell, M. Newman, M.A. Amantea, and L.D. Kaplan Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma J. Clin. Pharmacol. 36 1996 55 63 (Pubitemid 26058811)
65. M.E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D.G. Kieback, P. Tomczak, S.P. Ackland, F. Orlandi, L. Mellars, L. Alland, and C. Tendler Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449 (Pubitemid 38444547)
66. R.Z. Orlowski, A. Nagler, P. Sonneveld, J. Blade, R. Hajek, A. Spencer, J. San Miguel, T. Robak, A. Dmoszynska, N. Horvath, I. Spicka, H.J. Sutherland, A.N. Suvorov, S.H. Zhuang, T. Parekh, L. Xiu, Z. Yuan, W. Rackoff, and J.L. Harousseau Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J. Clin. Oncol. 25 2007 3892 3901 (Pubitemid 47477266)
67. R.Z. Orlowski, P.M. Voorhees, R.A. Garcia, M.D. Hall, F.J. Kudrik, T. Allred, A.R. Johri, P.E. Jones, A. Ivanova, H.W. Van Deventer, D.A. Gabriel, T.C. Shea, B.S. Mitchell, J. Adams, D.L. Esseltine, E.G. Trehu, M. Green, M.J. Lehman, S. Natoli, J.M. Collins, C.M. Lindley, and E.C. Dees Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood 105 2005 3058 3065
68. D. Papahadjopoulos, and A. Gabizon Stealth liposomes as tools for drug delivery J. Philipot, F. Schuber, Liposomes as Tools in Basic Research and Industry 1995 CRC Press Boca Raton 177 188
69. E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. Heywood, P.A. Vasey, B. Volgger, I. Vergote, S. Pignata, A. Ferrero, J. Sehouli, A. Lortholary, G. Kristensen, C. Jackisch, F. Joly, C. Brown, N. Le Fur, and A. du Bois Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J. Clin. Oncol. 28 2010 3323 3329
70. G. Putz, O. Schmah, J. Eckes, M.J. Hug, and K. Winkler Controlled application and removal of liposomal therapeutics: effective elimination of pegylated liposomal doxorubicin by double-filtration plasmapheresis in vitro J. Clin. Apher. 25 2010 54 62
71. R.M. Rifkin, S.A. Gregory, A. Mohrbacher, and M.A. Hussein Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial Cancer 106 2006 848 858 (Pubitemid 43238452)
72. J. Senior, and G. Gregoriadis Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components Life Sci. 30 1982 2123 2136 (Pubitemid 12066826)
73. J.J. Shah, R.Z. Orlowski, and S.K. Thomas Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma Ther. Clin. Risk Manag. 5 2009 151 159
74. K.M. Skubitz, and P.A. Haddad Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma Cancer 104 2005 361 366 (Pubitemid 40993264)
75. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792 (Pubitemid 32222155)
76. R. Solomon, and A.A. Gabizon Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin Clin. Lymphoma Myeloma 8 2008 21 32 (Pubitemid 351449716)
77. J.A. Sparano, A.N. Makhson, V.F. Semiglazov, S.A. Tjulandin, O.I. Balashova, I.N. Bondarenko, N.V. Bogdanova, G.M. Manikhas, G.P. Oliynychenko, V.A. Chatikhine, S.H. Zhuang, L. Xiu, Z. Yuan, and W.R. Rackoff Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study J. Clin. Oncol. 27 2009 4522 4529
78. S. Stewart, H. Jablonowski, F.D. Goebel, K. Arasteh, M. Spittle, A. Rios, D. Aboulafia, J. Galleshaw, and B.J. Dezube Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group J. Clin. Oncol. 16 1998 683 691 (Pubitemid 28135616)
79. J. Szebeni, F. Muggia, A. Gabizon, and Y. Barenholz Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention Adv. Drug Deliv. Rev. 63 2011 1020 1030
80. M. Travitzky, E. Libson, I. Nemirovsky, I. Hadas, and A. Gabizon Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma Anticancer Drugs 14 2003 247 250 (Pubitemid 36418945)
81. O. Tredan, C.M. Galmarini, K. Patel, and I.F. Tannock Drug resistance and the solid tumor microenvironment J. Natl. Cancer Inst. 99 2007 1441 1454
82. A. Udhrain, K.M. Skubitz, and D.W. Northfelt Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma Int. J. Nanomedicine 2 2007 345 352 (Pubitemid 350047778)
83. B. Uziely, S. Jeffers, R. Isacson, K. Kutsch, D. Wei-Tsao, Z. Yehoshua, E. Libson, F.M. Muggia, and A. Gabizon Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies J. Clin. Oncol. 13 1995 1777 1785
84. J. Vaage, E. Barbera-Guillem, R. Abra, A. Huang, and P. Working Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts Cancer 73 1994 1478 1484 (Pubitemid 24072557)
85. M. von Mehren, R.J. Schilder, J.D. Cheng, E. Temmer, T.M. Cardoso, F.G. Renshaw, E. Bayever, P. Zannikos, Z. Yuan, and R.B. Cohen A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies Ann. Oncol. 19 2008 1802 1809
86. A.C. Wolff, M. Wang, H. Li, M.R. Pins, F.J. Pretorius, K.M. Rowland, J.A. Sparano, and N.E. Davidson Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198 Breast Cancer Res. Treat. 121 2010 111 120
87. M.C. Woodle, and D.D. Lasic Sterically stabilized liposomes Biochim. Biophys. Acta 1113 1992 171 199
88. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, and R.K. Jain Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55 1995 3752 3756
89. F. Yuan, M. Leunig, S.K. Huang, D.A. Berk, D. Papahadjopoulos, and R.K. Jain Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res. 54 1994 3352 3356 (Pubitemid 24225946)